OVID
Ovid Therapeutics Inc. Health Care Pharmaceutical Preparations Russell 3000
$2.54Close
$330.7MMarket cap
$1.20 – $2.9652-week range
Nov 11, 2026Next report
Highlights
Strengths
- Leading the market RS 85 · stronger than 85% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 150/200-day, 50-day under the 150/200-day
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 17.6%
price change
1mo
up 2.0%
price change
12-month return
up 85%
market up 11% ·
its own up 64%
F-score
—
— Not assessed
Altman Z
6.45
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.5×
price / book
Earnings yield
down 13.4%
EBIT / enterprise value
Cheaper than
25%
of the market · expensive
Revenue growth
up 1181%
year on year
EPS growth
—
latest quarter
Sales growth
down 88%
latest quarter · +12 pts
ROE
down 17%
return on equity
Free cash margin
down 529%
-$38.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.1%
$0.18 a day · 2×ATR $2.18
RS
85 / 99
vs the universe
Trend
6 / 8
under the 150/200-day, 50-day under the 150/200-day
Relative volume
1.9×
vs 50-day average
Up/down volume
0.96
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 6 of 8
- Price above the 150 and 200-day averages: fails
- 50-day average above the 150 and 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 83.3% over the year, from 71m to 130m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Mar 18, 2026
Financials
- Net -240%
- Free cash -529%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $208.4M | $1.5M | $392,000 | $566,000 | $7.3M |
| Operating income | -$81.4M | $124.2M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| Net income | -$81.0M | $122.8M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Net margin | -642% | 59% | -3605% | -13342% | -4664% | -240% |
| Earnings per share | -$1.39 | $1.80 | -$0.77 | -$0.74 | — | — |
| Free cash flow | -$51.7M | $118.4M | -$56.5M | -$45.8M | -$56.0M | -$38.3M |
| Free cash margin | -410% | 57% | -3757% | -11689% | -9899% | -529% |
| Cash | $72.0M | $187.8M | $44.9M | $27.0M | $26.3M | $13.2M |
| Shareholders' equity | $43.6M | $179.7M | $132.3M | $87.8M | $68.2M | $130.7M |
| Shares outstanding | 65.74m | 70.36m | 70.47m | 70.69m | 71.01m | 130.18m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 18, 2026 | Annual ↗ | Dec 31, 2025 | 77d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 11, 2025 | Annual ↗ | Dec 31, 2024 | 70d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 8, 2024 | Annual ↗ | Dec 31, 2023 | 68d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 13, 2026 | Exhibits only ↗ |
| Jul 8, 2026 | Director or officer change ↗ |
| Jun 11, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Director or officer change ↗ |
| May 12, 2026 | Exhibits only ↗ |
| Apr 20, 2026 | Other events ↗ |
| Mar 18, 2026 | Material agreement · Results · Unregistered share sale ↗ |
| Dec 18, 2025 | Other events ↗ |
| Dec 11, 2025 | Shareholder vote ↗ |
| Nov 12, 2025 | Results · Director or officer change ↗ |
| Oct 3, 2025 | Material agreement · Unregistered share sale · Charter or bylaws · Other events ↗ |
| Sep 16, 2025 | Other events ↗ |